Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

88 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Stromal cell inhibition of anti-CD20 antibody mediated killing of B-cell malignancies.
Fagnano E, Pendharkar S, Colton M, Jones PN, Sallan MC, Klymenko T, Braun A, Klein C, Honeychurch J, Cheadle EJ, Illidge TM. Fagnano E, et al. Among authors: illidge tm. Front Cell Dev Biol. 2023 Oct 31;11:1270398. doi: 10.3389/fcell.2023.1270398. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 38020903 Free PMC article.
Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1.
Mukherjee D, Romano E, Walshaw R, Zeef LAH, Banyard A, Kitcatt SJ, Cheadle EJ, Tuomela K, Pendharkar S, Al-Deka A, Salerno B, Raby S, Mills IG, Honeychurch J, Illidge TM. Mukherjee D, et al. Among authors: illidge tm. Oncoimmunology. 2023 Jun 15;12(1):2223094. doi: 10.1080/2162402X.2023.2223094. eCollection 2023. Oncoimmunology. 2023. PMID: 37332616 Free PMC article.
The CD40 agonist HERA-CD40L results in enhanced activation of antigen presenting cells, promoting an anti-tumor effect alone and in combination with radiotherapy.
Frankish J, Mukherjee D, Romano E, Billian-Frey K, Schröder M, Heinonen K, Merz C, Redondo Müller M, Gieffers C, Hill O, Thiemann M, Honeychurch J, Illidge T, Sykora J. Frankish J, et al. Front Immunol. 2023 May 26;14:1160116. doi: 10.3389/fimmu.2023.1160116. eCollection 2023. Front Immunol. 2023. PMID: 37304285 Free PMC article.
A Retrospective Chart Review of Treatment Patterns and Overall Survival among a Cohort of Patients with Relapsed/Refractory Mycosis Fungoides in France, Germany, Italy, Spain and the United Kingdom.
Assaf C, Illidge TM, Waser N, He M, Li T, Zomas A, Bent-Ennakhil N, Little M, Ortiz-Romero PL, Pimpinelli N, Dalal M, Bagot M. Assaf C, et al. Among authors: illidge tm. Cancers (Basel). 2023 Nov 30;15(23):5669. doi: 10.3390/cancers15235669. Cancers (Basel). 2023. PMID: 38067371 Free PMC article.
Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control.
Nakamura K, Karmokar A, Farrington PM, James NH, Ramos-Montoya A, Bickerton SJ, Hughes GD, Illidge TM, Cadogan EB, Davies BR, Dovedi SJ, Valge-Archer V. Nakamura K, et al. Among authors: illidge tm. Clin Cancer Res. 2021 Aug 1;27(15):4353-4366. doi: 10.1158/1078-0432.CCR-20-3701. Epub 2021 May 19. Clin Cancer Res. 2021. PMID: 34011558 Free PMC article.
88 results